Zai Lab (ZLAB) Stock Could Look Pricey As Pipeline Hopes Face A Test

Zai Lab stock has rebounded sharply in recent months, yet long term shareholders are still facing heavy losses and the broader valuation checks do not flag the shares as a clear bargain or as clearly expensive. The current debate is whether the recent strength in the share price already reflects what the market expects from the business.

• Over the past 5 years, Zai Lab has delivered a decline of about 80.9%, which means many earlier investors are still deeply under water despite the recent recovery.
• The valuation now hinges on whether the company can turn its pipeline and commercial portfolio into more consistent cash generation, while investors remain alert to the risk that high research and development needs and execution setbacks could weigh on profitability for longer.
• The overall value score of 3 out of 6 points to a mixed picture rather than a clear bargain or clear overvaluation based on the broader checks.

For investors, the debate is whether Zai Lab's recent share price rebound still leaves room for an attractive long term return based on today’s valuation checks.

Compare Zai Lab's mixed valuation score and uneven returns with hand picked companies in the 47 high quality undervalued stocks that also combine quality fundamentals with more grounded pricing.

Does Zai Lab Look Pricey on Sales?

P/S is often used for companies like Zai Lab where earnings are not yet a steady guide and investors focus more on the revenue base. Zai Lab currently trades on a P/S of 6.5x, which is above the peer average of 5.2x but below the wider biotech industry average of 13.2x. That places the stock somewhere between its direct peers and the broader sector on simple sales based comparisons.

The fair P/S ratio from the model is 3.2x, which is roughly half of where Zai Lab trades today. That gap suggests the current share price builds in a richer value for each dollar of revenue than the model implies based on the company’s risk profile, margins and growth assumptions. On this framework, investors are paying a premium for Zai Lab that other biotechs with similar characteristics are not receiving.

On the P/S multiple, Zai Lab stock currently screens as overvalued relative to what the model treats as a more reasonable sales based level.

See what the numbers say about this price — find out in our valuation breakdown.

The Zai Lab Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Zai Lab pick up where the valuation checks leave off and set out the kind of future growth, margins and earnings path that would need to play out for the stock to be worth materially more or materially less than today’s price. Instead of a single output from a ratio or model, they describe the future that figure assumes. You can watch this over time on Simply Wall St's Community page as Zai Lab's story develops.

Community narratives on Zai Lab are far apart, with one side leaning into a global growth story and the other focused on regulatory and pricing pressure.

Bull case: 46% undervalued

"Current market valuations do not appear to fully reflect Zai Lab's unique ability to access, acquire, and rapidly develop global first and China originated innovation..."

Read the full Bull Case to see why Zai Lab could be undervalued

Bear case: 8% overvalued

"Stricter regulatory controls, pricing pressure, and reimbursement hurdles in China threaten sustainable revenue growth and delay earnings from new drug launches..."

Read the full Bear Case to see why Zai Lab could be overvalued

Do you think there's more to the story for Zai Lab? Head over to our Community to see what others are saying!

The Bottom Line

Zai Lab currently screens as overvalued on simple sales multiples, which points to a market that already prices in a fair amount of optimism. The mixed overall valuation checks suggest the stock is not an obvious bargain, yet also not priced for failure. For you, the crux is whether Zai Lab can turn its pipeline and existing portfolio into stronger and more durable cash generation. If that does not materialise in a convincing way, the current premium to peers on P/S could prove hard to justify over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com